butalbital and acetaminophen · BUTALBITAL 50 mg/1; ACETAMINOPHEN 300 mg/1 · Tablet · Oral · Burel Pharmaceuticals, LLC
NDC 35573-0455-02 · 100 TABLET in 1 BOTTLE · ANDA · View full market →
8 companies supply this market — a reasonable cushion if one runs into trouble. The price has fallen 54% in a year, to $1.53 per unit — and generics that get this cheap tend to get abandoned rather than defended. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.
Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.
The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026
OAI inspection at a producing facility (24 months) · sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
No FDA shortage reports for this drug or its presentations.
No enforcement reports list this package NDC.
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Par Health | BUTALBITAL 50 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 27, 2026 | Sep 3, 2026 |
| Aarkish Pharmaceuticals NJ Inc. | ACETAMINOPHEN 300 mg/1; BUTALBITAL 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amici Pharma, Inc. | ACETAMINOPHEN 325 mg/1; BUTALBITAL 25 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amici Pharma, Inc. | ACETAMINOPHEN 325 mg/1; BUTALBITAL 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Amici Pharma, Inc. | ACETAMINOPHEN 300 mg/1; BUTALBITAL 50 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Burel Pharmaceuticals, LLC | BUTALBITAL 50 mg/1; ACETAMINOPHEN 300 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Burel Pharmaceuticals, LLC | BUTALBITAL 50 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| El Dorado Distributors LLC | BUTALBITAL 50 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Larken Laboratories, Inc. | BUTALBITAL 50 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Quagen Pharmaceuticals Llc | BUTALBITAL 50 mg/1; ACETAMINOPHEN 300 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Quagen Pharmaceuticals Llc | BUTALBITAL 50 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Larken Laboratories, Inc. | BUTALBITAL 25 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 26, 2026 | Aug 31, 2026 |
| Endo USA | BUTALBITAL 50 mg/1; ACETAMINOPHEN 325 mg/1 | Aug 26, 2026 | Aug 26, 2026 |
| Larken Laboratories, Inc. | BUTALBITAL 325 mg/1; ACETAMINOPHEN 25 mg/1 | Jul 22, 2026 | Aug 20, 2026 |
| Burel Pharmaceuticals, LLC | BUTALBITAL 325 mg/1; ACETAMINOPHEN 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Burel Pharmaceuticals, LLC | BUTALBITAL 300 mg/1; ACETAMINOPHEN 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| El Dorado Distributors LLC | BUTALBITAL 325 mg/1; ACETAMINOPHEN 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Endo USA | BUTALBITAL 325 mg/1; ACETAMINOPHEN 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Larken Laboratories, Inc. | BUTALBITAL 325 mg/1; ACETAMINOPHEN 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Quagen Pharmaceuticals Llc | BUTALBITAL 300 mg/1; ACETAMINOPHEN 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Quagen Pharmaceuticals Llc | BUTALBITAL 325 mg/1; ACETAMINOPHEN 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Larken Laboratories, Inc. | ACETAMINOPHEN 325 mg/1; BUTALBITAL 25 mg/1 | Jul 15, 2026 | Jul 19, 2026 |
| Burel Pharmaceuticals, LLC | ACETAMINOPHEN 300 mg/1; BUTALBITAL 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Burel Pharmaceuticals, LLC | ACETAMINOPHEN 325 mg/1; BUTALBITAL 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| El Dorado Distributors LLC | ACETAMINOPHEN 325 mg/1; BUTALBITAL 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Endo USA | ACETAMINOPHEN 325 mg/1; BUTALBITAL 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Larken Laboratories, Inc. | ACETAMINOPHEN 325 mg/1; BUTALBITAL 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Quagen Pharmaceuticals Llc | ACETAMINOPHEN 325 mg/1; BUTALBITAL 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Quagen Pharmaceuticals Llc | ACETAMINOPHEN 300 mg/1; BUTALBITAL 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
DrugDashboards, "Butalbital And Acetaminophen — NDC 35573-0455-02," retrieved September 3, 2026, https://drugdashboards.com/drug/35573045502.
Free to cite with attribution — see how the data is put together.